Loading
A phase 1/2 trial of OH2 injection, with or without irinotecan or HX008 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
OH2 Oncolytic Viral Therapy in Solid Tumors is a phase 1/2 interventional study registered as NCT03866525 by Binhui Biopharmaceutical Co., Ltd., with 300 participants planned, started 2019-04-02 and due to reach its primary completion in 2025-08-30. Interventions recorded: OH2 injection, with or without irinotecan or HX008.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Binhui Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Binhui Biopharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/